Comparison
MGF (Mechano Growth Factor) vs. Tesamorelin
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Growth
Growth
CAS no.
12-Aminosäuren-C-terminales E-Domänen-Peptid (Sequenz nicht standardisiert)
901758-09-6
Molecular weight
2867.2 g/mol
5135.83 g/mol
Half-life
0.1 h
0.4 h
Sequence
YQPPSTNKNTKSQRRKGSTFEERKtrans-3-hexenoyl-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH2Mechanism of action
MGF (Mechano Growth Factor)
The IGF-1 gene produces multiple isoforms by alternative splicing. IGF-1Ec is upregulated after mechanical muscle loading; the C-terminal E-domain is cleaved from the mature IGF-1 protein and appears to have independent effects on satellite cells. The exact receptor binding of the E-domain is not established; a classical IGF-1R effect is unlikely since mature IGF-1 is responsible. In cell-culture studies, stimulation of myoblast proliferation and differentiation has been observed.
Tesamorelin
Tesamorelin is an N-terminally modified 44-amino-acid version of human GHRH(1-44). A 3-hexenoyl modification protects against rapid dipeptidyl-peptidase-IV cleavage. Binding to the pituitary GHRH receptor stimulates endogenous pulsatile growth-hormone secretion and consequently hepatic IGF-1 production.
Evidence base
Highest evidence
Animal model
Human RCT
Studies
4
4
of which in humans
0
4
Effects recorded
3
3
Open conflicts
1
1
Documented adverse events
1
2
Legal status
Full entries
Frequently asked questions
- What is the difference between MGF (Mechano Growth Factor) and Tesamorelin?
- MGF (Mechano Growth Factor) is classified as "Growth", while Tesamorelin is classified as "Growth". MGF (Mechano Growth Factor): Synthetic peptide corresponding to the C-terminal E-domain of the IGF-1 splice variant IGF-1Ec. Described in preclinical studies as a 'mechano-induced' skeletal muscle repair factor. No marketing approval; clinical use largely confined to the black market. Tesamorelin: Stabilised GHRH analog (growth-hormone-releasing hormone). FDA-approved in 2010 as Egrifta for reduction of abdominal lipohypertrophy in HIV-associated lipodystrophy. Not approved for the general population. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, MGF (Mechano Growth Factor) or Tesamorelin?
- The highest available evidence level is "Animal model" for MGF (Mechano Growth Factor) and "Human RCT" for Tesamorelin. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of MGF (Mechano Growth Factor) and Tesamorelin in Germany and the United States?
- Germany: MGF (Mechano Growth Factor) — Unapproved, Tesamorelin — Unapproved. United States: MGF (Mechano Growth Factor) — Unapproved, Tesamorelin — Prescription. These are factual summaries with source and review date on the individual pages.